pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

cstone-pharmaceuticals PRESS RELEASE ARCHIVE

Jan 2, 2022

CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration

Dec 22, 2021

Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for Sugemalimab (Cejemly) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer in Combination with Chemotherapy

Nov 23, 2021

CStone Pharmaceuticals y Jiangsu Hengrui Pharmaceuticals anuncian una alianza estratégica y un acuerdo de licencia exclusivo para anticuerpos monoclonales anti-CTLA-4 CS1002 en la Gran China Latin America - español España - español USA - English USA - English

Nov 22, 2021

CStone Pharmaceuticals und Jiangsu Hengrui Pharmaceuticals geben strategische Partnerschaft und exklusive Lizenzvereinbarung für den monoklonalen Anti-CTLA-4-Antikörper CS1002 in Greater China bekannt Deutschland - Deutsch España - español USA - English USA - English

Nov 21, 2021

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China USA - English España - español USA - English

Jun 28, 2020

Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China

Jan 6, 2020

CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma

Aug 15, 2019

CStone Pharmaceuticals Reports First Half 2019 Financial Results

Apr 4, 2019

CStone Pharmaceuticals presented poster of pre-clinical result for CS1003 at AACR

Feb 26, 2019

CStone Pharmaceuticals listed on the Hong Kong Stock Exchange today

Dec 21, 2018

CStone Pharmaceuticals announces initiation of CS1001 Phase I Study in U.S., patient enrollment under way

Dec 10, 2018

CStone Pharmaceuticals Appoints Former MSD Global Oncology Early Development Executive Director Archie Tse, M.D., Ph.D., as the newly established SVP, Chief Translation Medicine Officer

Jul 22, 2018

CStone Pharmaceuticals Appoints Former Goldman Sachs Executive Richard Yeh as CFO

Jun 4, 2018

Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China

Nov 3, 2017

Opening Ceremony of CStone Pharmaceuticals' Suzhou Translational Medicine Research Center and an associated Immuno-Oncology Forum was Successfully Held in Suzhou

Oct 18, 2016

CStone Pharmaceuticals' PD-L1 monoclonal antibody IND has been formally accepted by the CFDA

Jul 3, 2016

Innovative Biotech Company CStone Pharmaceuticals Receives 150 million Dollars in Series A Financing to Focus on Addressing the Specific Needs of Chinese Patients

Google Analytics Alternative